Observations on 6-MAM (6-Monoacetylmorphine) in Urine

Amadeo Pesce*, Kevin Krock, Dennis Ritz, Agnes Cua, Richard Thomas and Joyce Nickley

Abstract

Heroin (diacetylmorphine) is made by acetylation of the 3 and 6 positions of the morphine molecule allowing it to rapidly cross the blood brain barrier. Once taken, it is rapidly de-acylated in two steps. First, the acetyl group from the 3 position is removed, forming 6-monoacetylmorphine (6-MAM). Second, the acetyl group on the 6 position is hydrolyzed, forming morphine.

Although the major excreted products of heroin metabolism are morphine and morphine glucuronide, detection of heroin use is achieved by monitoring the presence of the intermediate metabolite 6-MAM in urine. The only source of this metabolite is heroin.

Workplace testing guidelines set the cut-off for 6-MAM at 10 ng/ml, implying that only 0.5% of the excreted morphine would be 6-MAM. Reviews of our urine samples positive for 6-MAM showed a significant number were above 1000 ng/mL. We attempted to determine the possible reason for the high 6-MAM urine concentrations.

Methods

The study was approved by Aspire IRB of Santee California. Patient specimens were referred from pain physician practices and rehabilitation clinics as part of their compliance monitoring programs. A high sensitivity quantitative LC-MS/MS method was created that measured concentrations of 71 drugs and metabolites including morphine and 6-MAM [13].

Results

Figure 1 is a frequency distribution curve of the 6-MAM results displayed as a semi-logarithmic plot [14]. The Y axis displays the observed number of observations for 0.1 log unit. The X axis is the observed urinary concentration of 6-MAM. More than 25% of the concentrations were greater than 1000 ng/mL. Our patient population includes a large number from addiction recovery facilities.

Discussion and Conclusion

More than 25% of the high 6-MAM concentrations we observed in this study (N=712) were above 1000 ng/mL (Figure 1). Based on previously published studies such as those of Anderson et al. [15], we expected the great majority of our results to be in the range of 10 to 1000 ng/mL. That study reported observed median values of 328 and 265 ng/mL.

Possible explanations for the unexpected high concentrations of 6-MAM include, esterase inhibitors, genetic variance and the incomplete synthesis of diacetylmorphine.
The conversion of 6-MAM to morphine is performed by Carboxylesterase-2 [16-19]. These esterase enzymes have polymorphic variability. This raises the possibility that the high values were due to inter-individual differences in the metabolic formation of morphine from 6-MAM. This possibility was ruled out by Anderson et al. [15] because they observed great variances in the excreted ratio of 6-MAM to morphine in the same patient.

![Figure 1: Observations of 6-MAM.](image)

Since polymorphisms cannot explain the high concentrations of 6-MAM with low concentrations of morphine, Anderson et al. hypothesized that a drug–drug inhibition interaction might be responsible. They presented data showing that a derivative of thebaine formed during the heroin production process is a strong inhibitor of the de-acylation reaction [15].

A third possibility is that the high 6-MAM concentrations are due to the impurity of the administered heroin, namely incomplete acetylation of morphine. Heroin brought into the United States from Mexico can consist of significantly more 6-MAM than heroin that enters into the country from the Mideast. This heroin from Mexico is called "black tar" heroin due to its appearance. Black tar heroin is the result of crude and cheaper synthetic synthesis methods [20]. Our tentative conclusion is that high concentrations of 6-MAM in urine probably reflect high concentrations of 6-MAM in the administered drug and inhibition of its breakdown by carboxylesterase by impurities of a thebaine product made during its synthesis.

References

1. Barceloux DG (2012) Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons, Hoboken NJ 549.
2. Baselt RC (2011) Disposition of Toxic Drugs and Chemicals in Man Biomedical Publications Seal Beach CA 793-797.
3. Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH (2006) Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1: 109-118.
4. Mandatory Guidelines and Proposed Revisions to Mandatory Guidelines for Federal Workplace Drug Testing Programs; Notices Section 2.4 Laboratory Analysis Procedures (f) (1) confirmatory drug test. Federal Register. Vol. 69, No. 71, Tuesday, Notices page 19659, April 13, 2004.
5. Reisfeld GM, Salazar E, Bertholf RL (2007) Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 37: 301-314.
6. Procedures for Transportation Workplace Drug and Alcohol Testing Programs: 6-acetylmorphine (6-AM) Testing (2012).
7. Cone EJ, Welch P, Mitchell JM, Paul BD (1991) Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times J Anal Toxicol 15: 1-7.
8. Skopp G, Ganssmann B, Cone EJ, Aderjan R (1997) Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. J Anal Toxicol 21: 105-111.
9. Gyr E, Brenneisen R, Bourquin D, Lehmann T, Vonlanthen D, et al. (2000) Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependent, a two-patient pilot study within a heroin-assisted treatment program. Int Clin Pharmacol Ther 38: 486-491.
10. Smith ML, Shimomura ET, Summers J, Paul BD, Jenkins AJ, et al. (2001) Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin J Anal Toxicol 25: 504-514.
11. Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, et al. (2003) Pharmacokinetics of high doses of intra-muscular and oral heroin in narcotic addicts. Clin Pharmacol Ther 74: 341-352.
12. Glass LR, Ingalls ST, Schilling CL, Hoppel CL (1997) Atypical urinary opiate excretion pattern. J Anal Toxicol 6: 509-514.
13. Krock K, Pesce A, Ritz D, Thomas R, Cua A, et al. (2017) Lower Cutoff for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance. Pain Physician 20: E1107-1113.
14. Pesce A, West C, West R, Crews B, Mikel C, et al. (2010) Reference intervals: A novel approach to detect drug abuse in a pain patient population. J Opioid Manag 6: 341-350.
15. Andersson M, Björkhem-Bergman L, Beck O (2015) Possible mechanism for inhibition of morphine formation from 6-acetylmorphine after intake of street heroin. Forensic Sci Int 252: 150-156.
16. Potter PM, Wadkins RM (2006) Carboxylesterases—detoxifying enzymes and targets for drug therapy. Curr Med Chem 13: 1045-1054.
17. Wheelock CE, Shan G, Ottea J (2005) Overview of carboxylesterases and their role in the metabolism of insecticides. J Pesticide Sci 30: 75-83.
18. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, et al. (2004) Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84: 661-668.
19. Black tar heroin Barceloux D.G. Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants John Wiley & Sons, Hoboken, NJ 2012 page 549.
20. Wikipedia contributors. (2018, August 23). Black tar heroin. In Wikipedia, The Free Encyclopedia, August 2, 2018.